Get the latest Science News and Discoveries
Sarcoma clinical trial funded by stand up to cancer reduces risk of relapse by 43% - EurekAlert
For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults, a breakthrough that reduces the risk of relapse by 43% at two years and will likely impact clinical practice for these cancer types.
None
Or read this on Eureka Alert